|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07D 519/00 | (2006.01) |
| A61P 31/12 | (2006.01) | ||
| A61K 31/55 | (2006.01) |
| (11) | Number of the document | 2024375 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07761873.4 |
| Date of filing the European patent application | 2007-05-04 | |
| (97) | Date of publication of the European application | 2009-02-18 |
| (45) | Date of publication and mention of the grant of the patent | 2011-03-09 |
| (46) | Date of publication of the claims translation | 2011-06-27 |
| (86) | Number | PCT/US2007/068209 |
| Date | 2007-05-04 |
| (87) | Number | WO 2007/136982 |
| Date | 2007-11-29 |
| (30) | Number | Date | Country code |
| 801125 P | 2006-05-17 | US | |
| 802005 P | 2006-05-19 | US | |
| 852084 P | 2006-10-16 | US | |
| 894757 P | 2007-03-14 | US |
| (72) |
BENDER, John A., US
DING, Min, US
GENTLES, Robert G., US
HEWAWASAM, Piyasena, US
|
| (73) |
Bristol-Myers Squibb Holdings Ireland Unlimited Company,
Hinterbergstrasse 16, 6312 Steinhausen,
CH
|
| (74) |
Marius JAKULIS - JASON,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Su ciklopropilu sulieti indolbenzazepinai, kaip HCV NS5B inhibitoriai |
| CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS |
| Payment date | Validity (years) | Amount | |
| 2019-04-25 | 13 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2020-05-04 |